{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T16:54:04Z","timestamp":1784825644949,"version":"3.55.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T00:00:00Z","timestamp":1688428800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.rmed.2023.107334","type":"journal-article","created":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T12:08:49Z","timestamp":1688040529000},"page":"107334","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Efficacy of mometasone\/indacaterol\/glycopyrronium in patients with inadequately controlled asthma with respect to baseline eosinophil count: Post hoc analysis of IRIDIUM study"],"prefix":"10.1016","volume":"217","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0774-3942","authenticated-orcid":false,"given":"Konstantinos","family":"Kostikas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge F.","family":"Maspero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2498-9859","authenticated-orcid":false,"given":"Kenneth R.","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Mezzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Jaumont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4115-5362","authenticated-orcid":false,"given":"Richard","family":"van Zyl-Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmed.2023.107334_bib2","article-title":"Global strategy for asthma management and prevention","year":"2022","journal-title":"Global Initiative for Asthma (GINA)"},{"key":"10.1016\/j.rmed.2023.107334_bib4","first-page":"1","article-title":"A review of the unique drug development strategy of indacaterol acetate\/glycopyrronium bromide\/mometasone furoate: a first-in-class, once-daily, single-inhaler, fixed-dose combination treatment for asthma","author":"Brittain","year":"2022","journal-title":"Adv. Ther."},{"issue":"10","key":"10.1016\/j.rmed.2023.107334_bib5","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S2213-2600(20)30190-9","article-title":"Once-daily, single-inhaler mometasone\u2013indacaterol\u2013glycopyrronium versus mometasone\u2013indacaterol or twice-daily fluticasone\u2013salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study","volume":"8","author":"Kerstjens","year":"2020","journal-title":"Lancet Respir. Med."},{"issue":"5","key":"10.1016\/j.rmed.2023.107334_bib6","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1365-2222.2008.02958.x","article-title":"Eosinophils: biological properties and role in health and disease","volume":"38","author":"Hogan","year":"2008","journal-title":"Clin. Exp. Allergy"},{"issue":"1","key":"10.1016\/j.rmed.2023.107334_bib7","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1183\/09031936.00201813","article-title":"Importance of concomitant local and systemic eosinophilia in uncontrolled asthma","volume":"44","author":"Schleich","year":"2014","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2023.107334_bib8","author":"Moore"},{"key":"10.1016\/j.rmed.2023.107334_bib9","series-title":"Eosinophilic Asthma. Asthma-Biological Evidences","author":"Mubarak","year":"2019"},{"issue":"1","key":"10.1016\/j.rmed.2023.107334_bib10","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S2213-2600(20)30389-1","article-title":"Efficacy and safety of once-daily single-inhaler triple therapy (FF\/UMEC\/VI) versus FF\/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial","volume":"9","author":"Lee","year":"2021","journal-title":"Lancet Respir. Med."},{"issue":"5","key":"10.1016\/j.rmed.2023.107334_bib11","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1080\/02770903.2018.1471708","article-title":"Treatment of severe, uncontrolled eosinophilic asthma: where we are heading","volume":"56","author":"Bernstein","year":"2019","journal-title":"J. Asthma"},{"issue":"2","key":"10.1016\/j.rmed.2023.107334_bib12","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s12016-018-8712-1","article-title":"Understanding asthma phenotypes, endotypes, and mechanisms of disease","volume":"56","author":"Kuruvilla","year":"2019","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.rmed.2023.107334_bib13","first-page":"53","article-title":"Diagnosis and management of eosinophilic asthma: a US perspective","volume":"7","author":"Walford","year":"2014","journal-title":"J. Asthma Allergy"},{"issue":"10","key":"10.1016\/j.rmed.2023.107334_bib14","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1080\/02770903.2017.1391281","article-title":"Biomarkers for differentiation of patients with asthma and chronic obstructive pulmonary disease","volume":"55","author":"Katoh","year":"2018","journal-title":"J. Asthma"},{"issue":"3","key":"10.1016\/j.rmed.2023.107334_bib15","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.chest.2021.04.013","article-title":"Eosinophilic and noneosinophilic asthma: an expert consensus framework to characterize phenotypes in a global real-life severe asthma cohort","volume":"160","author":"Heaney","year":"2021","journal-title":"Chest"},{"issue":"8","key":"10.1016\/j.rmed.2023.107334_bib16","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/nm.3300","article-title":"Eosinophils in the spotlight: eosinophilic airway inflammation in nonallergic asthma","volume":"19","author":"Brusselle","year":"2013","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.rmed.2023.107334_bib17","doi-asserted-by":"crossref","first-page":"191","DOI":"10.15586\/aei.v49i2.50","article-title":"Eosinophil: a central player in modulating pathological complexity in asthma","volume":"49","author":"Pritam","year":"2021","journal-title":"Allergol. Immunopathol."},{"issue":"4","key":"10.1016\/j.rmed.2023.107334_bib18","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.molmed.2005.02.002","article-title":"The role of eosinophils in the pathogenesis of asthma","volume":"11","author":"Kay","year":"2005","journal-title":"Trends Mol. Med."},{"issue":"1","key":"10.1016\/j.rmed.2023.107334_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12931-020-01558-y","article-title":"Determinants of response to inhaled extrafine triple therapy in asthma: analyses of TRIMARAN and TRIGGER","volume":"21","author":"Singh","year":"2020","journal-title":"Respir. Res."},{"issue":"4","key":"10.1016\/j.rmed.2023.107334_bib20","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.chest.2018.12.016","article-title":"Adding a LAMA to ICS\/LABA therapy: a meta-analysis of triple combination therapy in COPD","volume":"155","author":"Calzetta","year":"2019","journal-title":"Chest"},{"issue":"21","key":"10.1016\/j.rmed.2023.107334_bib21","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1056\/NEJMoa1814917","article-title":"Mometasone or tiotropium in mild asthma with a low sputum eosinophil level","volume":"380","author":"Lazarus","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.rmed.2023.107334_bib22","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.21037\/jtd.2018.05.139","article-title":"Clinical predictors of the effectiveness of tiotropium in adults with symptomatic asthma: a real-life study","volume":"10","author":"Cheng","year":"2018","journal-title":"J. Thorac. Dis."},{"issue":"3","key":"10.1016\/j.rmed.2023.107334_bib23","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.jaip.2017.08.037","article-title":"Tiotropium respimat add-on is efficacious in symptomatic asthma, independent of T2 phenotype","volume":"6","author":"Casale","year":"2018","journal-title":"J. Allergy Clin. Immunol. Pract.: In Pract."},{"issue":"2","key":"10.1016\/j.rmed.2023.107334_bib24","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3390\/life12020173","article-title":"The impact of 52-week single inhaler device triple therapy versus dual therapy on the mortality of COPD patients: a systematic review and meta-analysis of randomized controlled trials","volume":"12","author":"Lai","year":"2022","journal-title":"Life"},{"key":"10.1016\/j.rmed.2023.107334_bib25","series-title":"Mometasone\/indacaterol\/glycopyrronium Demonstrates Similar Efficacy in Men and Women: Post Hoc Analysis of IRIDIUM Study","author":"Raherison-Semjen","year":"2021"},{"issue":"1","key":"10.1016\/j.rmed.2023.107334_bib26","article-title":"Efficacy of one time per day, single-inhaler indacaterol\/glycopyrronium\/mometasone in patients with inadequately controlled asthma: post hoc analysis of IRIDIUM study in Asian population","volume":"8","author":"Sagara","year":"2021","journal-title":"BMJ Open Respir Res"}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611123002226?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611123002226?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T12:32:46Z","timestamp":1760617966000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611123002226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":24,"alternative-id":["S0954611123002226"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2023.107334","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of mometasone\/indacaterol\/glycopyrronium in patients with inadequately controlled asthma with respect to baseline eosinophil count: Post hoc analysis of IRIDIUM study","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2023.107334","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Novartis Pharma AG. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107334"}}